Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study.

Depressive symptoms, antidepressant use, and the incidence of diabetes in the Black Women's Health Study. Diabetes Care (2014) 1.48

Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry (2011) 1.29

Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia (2011) 1.28

Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care (2013) 1.25

Is ignorance bliss? Depression, antidepressants, and the diagnosis of prediabetes and type 2 diabetes. Health Psychol (2013) 1.24

NIDDK international conference report on diabetes and depression: current understanding and future directions. Diabetes Care (2014) 1.11

Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol (2011) 0.88

Depression as a predictor of weight regain among successful weight losers in the diabetes prevention program. Diabetes Care (2012) 0.87

Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs (2015) 0.86

Antidepressant use and glycemic control. Psychopharmacology (Berl) (2013) 0.82

Prevention of Diabetes Through the Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice. Curr Nutr Rep (2014) 0.81

Depressive symptoms, psychiatric medication use, and risk of type 2 diabetes: results from the Health and Retirement Study. Gen Hosp Psychiatry (2015) 0.80

Antidepressant use, depression, and new-onset diabetes among elderly Medicare beneficiaries. J Diabetes (2013) 0.79

Weight and metabolic effects of dietary weight loss and exercise interventions in postmenopausal antidepressant medication users and non-users: a randomized controlled trial. Prev Med (2013) 0.79

Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder. Psychopharmacology (Berl) (2011) 0.76

The association between Diabetes mellitus and Depression. J Med Life (2016) 0.76

Taking the Perspective that a Depressive State Reflects Inflammation: Implications for the Use of Antidepressants. Front Psychol (2012) 0.76

Antidepressant drug use and future diabetes risk. Diabetologia (2011) 0.76

Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study. Psychosom Med (2015) 0.75

The risk of new-onset diabetes in antidepressant users - A systematic review and meta-analysis. PLoS One (2017) 0.75

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74

Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry (2009) 3.33

Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42

Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract (2007) 1.59

The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab (2004) 1.24

Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). Int J Geriatr Psychiatry (2010) 1.05

Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors. Naunyn Schmiedebergs Arch Pharmacol (2000) 0.99

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79

Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 29.49

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35

Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97

Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57

MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50

Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med (2010) 8.70

Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care (2007) 8.43

TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med (2006) 7.75

Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med (2004) 6.77

Birth weight and risk of type 2 diabetes: a systematic review. JAMA (2008) 6.73

Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96

Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA (2002) 5.80

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med (2005) 5.76

Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res (2004) 5.74

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care (2011) 5.50

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47

Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med (2008) 5.40

Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38

Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ (2005) 5.34

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care (2005) 5.10

High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00

Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81

Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care (2008) 4.33

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet (2012) 4.33

Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab (2008) 4.29

Low serum testosterone and mortality in older men. J Clin Endocrinol Metab (2007) 4.27

Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care (2003) 4.22

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09

The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials (2002) 4.03

Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93

Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91

Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet (2002) 3.68

A genomewide single-nucleotide-polymorphism panel for Mexican American admixture mapping. Am J Hum Genet (2007) 3.39

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care (2003) 3.37

Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc (2007) 3.15

Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes (2002) 3.14

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 3.13

Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ (2003) 3.05

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 2.80

Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care (2007) 2.71

Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care (2003) 2.69

Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med (2002) 2.69

A search for variants associated with young-onset type 2 diabetes in American Indians in a 100K genotyping array. Diabetes (2007) 2.67

Testosterone and estradiol among older men. J Clin Endocrinol Metab (2005) 2.63

National standards for diabetes self-management education. Diabetes Care (2008) 2.60

Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation (2008) 2.56

Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr (2008) 2.55

Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes (2005) 2.46

Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44

Ethnic differences in visceral adipose tissue and type 2 diabetes: Filipino, African-American, and white women. Obes Res (2005) 2.44

Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes (2012) 2.43

Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42

Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol (2002) 2.41

Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation (2009) 2.41

Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2003) 2.40

Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ (2007) 2.37

National standards for diabetes self-management education. Diabetes Care (2009) 2.36

National standards for diabetes self-management education. Diabetes Care (2012) 2.36

A1C and diabetes diagnosis: The Rancho Bernardo Study. Diabetes Care (2009) 2.36

The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci (2006) 2.35

The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care (2012) 2.33

The association between quality of care and the intensity of diabetes disease management programs. Ann Intern Med (2006) 2.32

Ethnic-difference markers for use in mapping by admixture linkage disequilibrium. Am J Hum Genet (2002) 2.29

Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care (2002) 2.28

Mexican American ancestry-informative markers: examination of population structure and marker characteristics in European Americans, Mexican Americans, Amerindians and Asians. Hum Genet (2003) 2.27

The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27

Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol (2008) 2.26

National standards for diabetes self-management education. Diabetes Care (2007) 2.21

Gestational glucose tolerance and risk of type 2 diabetes in young Pima Indian offspring. Diabetes (2006) 2.21

Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med (2007) 2.17

Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes (2011) 2.17

Report of a National Heart, Lung, And Blood Institute Workshop: heterogeneity in cardiometabolic risk in Asian Americans In the U.S. Opportunities for research. J Am Coll Cardiol (2010) 2.15

Impact of a program to improve adherence to diabetes guidelines by primary care physicians. Diabetes Care (2002) 2.14

Psychological predictors of physical activity in the diabetes prevention program. J Am Diet Assoc (2006) 2.13